

Philogen to Present at Upcoming Conferences

Siena (Italy), 8 September 2022 - Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, today announces the conferences its management team will be participating in the coming months.

[European Society for Medical Oncology \(ESMO\) Congress 2022](#), 9-13 September

[European Association of Neuro-Oncology \(EANO\) Congress 2022](#), 15-18 September

[Emerging Technologies and Methodologies in Small Molecule Drug Discovery & Synthesis Symposium](#), 27-29 September

- *From Encoded Combinatorial Libraries To Targeted Therapeutics*, Prof. Dr. Dario Neri, Co-founder, Chief Executive and Chief Scientific Officer (28 September)

[Festival of Biologics Basel 2022](#), 2-4 November

- *Tripokin: tumor-targeted delivery of IL2 potentiated by TNF*, Roberto De Luca, PhD, Head of Antibody Therapeutics (2 November)
- *Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment of solid tumors*, Samuele Cazzamalli, Head of Small Molecule Therapeutics (2 November)

[10th International Symposium on DNA-Encoded Chemical Libraries](#), 3-4 November

- *Quantification of DEL selections and implications for good selection protocols*, Prof. Dr. Dario Neri, Co-founder, Chief Executive and Chief Scientific Officer (November 3)

[The Society for Immunotherapy of Cancer's \(SITC\) 37th Annual Meeting 2022](#), 8-12 November

- *Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent anti-tumor immunity against treatment-refractory glioblastoma*, Teresa Hemmerle, PhD, Senior Project Manager
- *A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer*, Roberto De Luca, PhD, Head of Antibody Therapeutics
- *Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling activation*, Sheila Dakhel, PhD, Senior Scientist
- *A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in cancer immunotherapy*, Abdullah Eisayed, PhD student at Philogen

[14th Annual PEGS Europe Protein & Antibody Engineering Summit 2022](#), 14-16 November

- *Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications*, Prof. Dr. Dario Neri, Co-founder, Chief Executive and Chief Scientific Officer

[TIDES Europe 2022](#), 16-18 November

- *Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast Activation Protein in solid lesions*, Samuele Cazzamalli, Head of Small Molecule Therapeutics

About Philogen Group

Philogen is an Italian-Swiss company active in the biotechnology sector, specialized in the research and development of pharmaceutical products for the treatment of highly lethal diseases. The Group mainly discovers and develops targeted anticancer drugs, exploiting high-affinity ligands for tumor markers (also called tumor antigens). These ligands - human monoclonal antibodies or small organic molecules - are identified using *Antibody Phage Display Libraries* and *DNA-Encoded Chemical Library* technologies.

The Group's main therapeutic strategy for the treatment of these diseases is represented by the so-called *tumor targeting*. This approach is based on the use of ligands capable of selectively delivering very potent therapeutic active ingredients (such as pro-inflammatory cytokines) to the tumor mass, sparing healthy tissues. Over the years, Philogen has mainly

developed monoclonal antibody-based ligands that are specific for antigens expressed in tumor-associated blood vessels, but not expressed in blood vessels associated with healthy tissues. These antigens are usually more abundant and more stable than those expressed directly on the surface of tumor cells. This approach, so called *vascular targeting*, is used for most of the projects pursued by the Group.

The Group's objective is to generate, develop and market innovative products for the treatment of diseases for which medical science has not yet identified satisfactory therapies. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights.

Although the Group's drugs are primarily oncology applications, the *targeting* approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases.

* * *

FOR MORE INFORMATION:

Philogen - Investor Relations

IR@philogen.com - Emanuele Puca | *Investor Relations*

Consilium Strategic Communications contacts

Mary-Jane Elliott, Davide Salvi

Philogen@consilium-comms.com